Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of BNZ132-1-40

NCT03046459 is registered in ClinicalTrials.gov with Bioniz Therapeutics as lead sponsor.

NCT NCT03046459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03046459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of BNZ132-1-40
Lead sponsor
Bioniz Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2016
Completion date
June 5, 2017
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy